A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors
NCT ID: NCT06796907
Last Updated: 2025-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
392 participants
INTERVENTIONAL
2025-03-04
2028-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
NCT02978755
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
NCT07286331
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06023862
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NCT03367871
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT05819892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Module 1 (GSK5733584 +/- Dostarlimab) Endometrial Cancer
GSK5733584
GSK5733584 will be administered intravenously (IV).
Dostarlimab
Dostarlimab will be administered IV.
Module 2 (GSK5733584 +/- Bevacizumab) Ovarian Cancer
GSK5733584
GSK5733584 will be administered intravenously (IV).
Bevacizumab
Bevacizumab will be administered IV.
Module 3 (GSK5733584 + Anticancer therapy 3 +/- Dostarlimab or Bevacizumab)
GSK5733584
GSK5733584 will be administered intravenously (IV).
Dostarlimab
Dostarlimab will be administered IV.
Bevacizumab
Bevacizumab will be administered IV.
Anticancer therapy 3
Anticancer therapy 3 will be administered IV.
Module 4 (GSK5733584 + Anticancer therapy 4 +/- Dostarlimab or Bevacizumab)
GSK5733584
GSK5733584 will be administered intravenously (IV).
Dostarlimab
Dostarlimab will be administered IV.
Bevacizumab
Bevacizumab will be administered IV.
Anticancer therapy 4
Anticancer therapy 4 will be administered IV.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK5733584
GSK5733584 will be administered intravenously (IV).
Dostarlimab
Dostarlimab will be administered IV.
Bevacizumab
Bevacizumab will be administered IV.
Anticancer therapy 3
Anticancer therapy 3 will be administered IV.
Anticancer therapy 4
Anticancer therapy 4 will be administered IV.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant capable of giving signed informed consent including compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
* Participants with pathologically confirmed advanced solid tumor specific for study arms (key local diagnostic molecular and/or immunophenotyping testing results/tumor cell phenotype results for confirmed diagnosis should be provided) with no more than 4 lines of prior systemic therapies. Please note:
1. Adjuvant +/- neoadjuvant considered one line of therapy
2. Maintenance therapy will be considered as part of the preceding line of therapy (i.e., not counted independently)
3. Unplanned addition or switching to a new drug in a different class is considered a separate line of therapy. If an agent in a regimen is switched to another agent in the same class due to toxicity or intolerance (e.g. hypersensitivity reaction) this is considered part of the same line (i.e. not counted independently).
* Requirements for tumor tissue samples: Archival or fresh tumor tissue is required for retrospective central assessment of B7H4 expression by immunohistochemistry (IHC) and other biomarker analysis. The archival tumor tissue should be from the most recent procedure (ideally obtained after the last anti-cancer treatment). If an archival tissue is not available a new biopsy should be performed, and the newly obtained tissue provided.
* Participants have at least one target lesion as assessed per RECIST 1.1. A target lesion is defined as a measurable lesion that has not undergone locoregional treatment such as irradiation or that has unequivocal progression following locoregional treatment, with the longest diameter of ≥ 10 millimeter (mm) at Baseline (for lymph node lesions, the short axis should be ≥ 15 mm).
* Participants have a life expectancy of at least 12 weeks per investigator assessment based on disease burden and extent of supportive care needed.
a. Participants with histologically documented, advanced (metastatic and/or unresectable) or recurrent endometrial cancer who have failed in adequate standard treatments, do not have effective standard treatment or are intolerant to standard of care, and who are not candidates for further curative external radiotherapy or brachytherapy.
1. Diagnosis of endometrial cancer with confirmed mismatch repair proficient (MMRp) or microsatellites stable (MSS) tumor status by local test.
2. Participants who have progressed on or are intolerant to at least 1 line of standard prior systemic therapy (including neoadjuvant or adjuvant as prior line), and who are not candidates for curative external radiotherapy or brachytherapy. Maintenance therapy will be considered part of the preceding line of therapy (i.e, not counted independently).
3. Participants naïve to anti-programmed death protein 1 and/or programmed death ligand 1 (PD\[L\]-1) anti-cancer therapy.
a. Participants with histologically or cytologically confirmed advanced epithelial ovarian cancer/fallopian tube/peritoneal cancer (any epithelial histology - mucinous, clear cell, carcinosarcoma, high/low grade serous, endometrioid) who have failed in adequate standard treatments, do not have effective standard treatment or are intolerant to standard of care.
1. Participants whose advanced ovarian cancer/fallopian tube/peritoneal cancer has relapsed more than 6 months from the last dose of platinum before enrollment, i.e., platinum sensitive.
2. Participants who have progressed on or are intolerant to at least 1 line of standard prior lines of chemotherapy and are not candidates for second cytoreductive surgery.
* Participants willing to use adequate contraception.
* Male participants:
* Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 6 months after the last dose of study intervention for Arms 1 to 3 and 11 Months after the last dose of study intervention for Arm 4:
* Refrain from donating sperm.
* Female participants:
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
* Is a Woman of non-childbearing potential (WONCBP) OR
* Is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective
* A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention
* Has an ECOG performance status of 0 to 1.
* Participants with normal organ and bone marrow function
Exclusion Criteria
* Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.
* Has known sensitivity to study intervention components, GSK5733584 (antibody-drug conjugate, antibody, free cytotoxin GSK5757810A) and combination partner, or its excipients or other allergy that, in the opinion of the investigator, contraindicates participation in the study.
* Has any following cardiological examination abnormality:
1. history in prior year of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, or clinically significant arrhythmia not controlled by standard of care therapy.
2. Corrected QT Interval (QTcF) \>450 millisecond (msec) or QTcF \>480 msec for participants with bundle branch block
* Any evidence of current interstitial lung disease (ILD) or pneumonitis or a prior history of ILD or non-infectious pneumonitis.
* Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).
* Clinically significant bleeding symptoms, significant bleeding tendency, or bleeding tumors within 1 month prior to the first dose of study treatment.
* Serious or poorly controlled hypertension, including history of hypertensive crisis, hypertensive encephalopathy; adjustment of antihypertensive medications due to poor blood pressure control within 2 weeks prior to the first dose of study treatment; systolic blood pressure ≥ 160 millimeter of mercury (mmHg) or diastolic blood pressure ≥ 100 mmHg during screening period.
* Has any active renal condition (e.g., infection, requirement for dialysis, or any other active significant renal condition or dehydrated condition that could affect the participant's safety).
* Participants with known history of Human immunodeficiency virus (HIV).
* Has an Alanine transaminase (ALT) value \>2.5x Upper Limit of Normal (ULN) and for participants with documented liver metastases/tumor infiltration has an ALT value \>5x ULN.
* Has a total bilirubin value \>1.5x ULN.
* Has received treatment with any cytotoxic chemotherapy drugs or other anti-tumor drugs (including endocrine therapy, molecular targeted therapy, immunotherapy, biotherapy, and investigational drug) within 30 days or 5 half-lives, whichever is shorter of a medicinal product prior to the first dose of study drug; or need to continue these drugs during the study.
* Use of strong or moderate inhibitors or inducers of CYP3A4, CYP2D6 and inhibitors or inducers of P-gp, and breast cancer resistance protein (BCRP) within 14 days prior to the first dose of study drug; or in need of continuing treatment with these drugs during the study.
* Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
CABA, , Argentina
GSK Investigational Site
Viedma, , Argentina
GSK Investigational Site
Liverpool, New South Wales, Australia
GSK Investigational Site
Wollongong, New South Wales, Australia
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Liège, , Belgium
GSK Investigational Site
Natal, , Brazil
GSK Investigational Site
Porto Alegre, , Brazil
GSK Investigational Site
São Paulo, , Brazil
GSK Investigational Site
Vitória, , Brazil
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Copenhagen, , Denmark
GSK Investigational Site
Helsinki, , Finland
GSK Investigational Site
Tampere, , Finland
GSK Investigational Site
Montpellier, , France
GSK Investigational Site
Pierre-Bénite, , France
GSK Investigational Site
Villejuif, , France
GSK Investigational Site
München, , Germany
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Pylaia Thessaloniki, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Chiba, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Punta Pacifica Panama City Panama, , Panama
GSK Investigational Site
Józefów, , Poland
GSK Investigational Site
Warsaw, , Poland
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Zaragoza, , Spain
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Ankara, , Turkey (Türkiye)
GSK Investigational Site
Ankara, , Turkey (Türkiye)
GSK Investigational Site
Istanbul, , Turkey (Türkiye)
GSK Investigational Site
Glasgow, , United Kingdom
GSK Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517147-31-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
223559
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.